Cargando…

The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies

As genomics advances reveal the cancer gene landscape, a daunting task is to understand how these genes contribute to dysregulated oncogenic pathways. Integration of cancer genes into networks offers opportunities to reveal protein–protein interactions (PPIs) with functional and therapeutic signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zenggang, Ivanov, Andrei A., Su, Rina, Gonzalez-Pecchi, Valentina, Qi, Qi, Liu, Songlin, Webber, Philip, McMillan, Elizabeth, Rusnak, Lauren, Pham, Cau, Chen, Xiaoqian, Mo, Xiulei, Revennaugh, Brian, Zhou, Wei, Marcus, Adam, Harati, Sahar, Chen, Xiang, Johns, Margaret A., White, Michael A., Moreno, Carlos S., Cooper, Lee A. D., Du, Yuhong, Khuri, Fadlo R., Fu, Haian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316855/
https://www.ncbi.nlm.nih.gov/pubmed/28205554
http://dx.doi.org/10.1038/ncomms14356
Descripción
Sumario:As genomics advances reveal the cancer gene landscape, a daunting task is to understand how these genes contribute to dysregulated oncogenic pathways. Integration of cancer genes into networks offers opportunities to reveal protein–protein interactions (PPIs) with functional and therapeutic significance. Here, we report the generation of a cancer-focused PPI network, termed OncoPPi, and identification of >260 cancer-associated PPIs not in other large-scale interactomes. PPI hubs reveal new regulatory mechanisms for cancer genes like MYC, STK11, RASSF1 and CDK4. As example, the NSD3 (WHSC1L1)–MYC interaction suggests a new mechanism for NSD3/BRD4 chromatin complex regulation of MYC-driven tumours. Association of undruggable tumour suppressors with drug targets informs therapeutic options. Based on OncoPPi-derived STK11-CDK4 connectivity, we observe enhanced sensitivity of STK11-silenced lung cancer cells to the FDA-approved CDK4 inhibitor palbociclib. OncoPPi is a focused PPI resource that links cancer genes into a signalling network for discovery of PPI targets and network-implicated tumour vulnerabilities for therapeutic interrogation.